Universität zu Köln

Marty, Francisco M. ORCID: 0000-0002-3708-8734, Cornely, Oliver A., Mullane, Kathleen M., Ostrosky-Zeichner, Luis, Maher, Rochelle M., Croos-Dabrera, Rodney, Lu, Qiaoyang, Lademacher, Christopher, Oren, Ilana, Schmitt-Hoffmann, Anne-Hortense, Giladi, Michael, Rahav, Galia and Perfect, John R. (2018). Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses, 61 (7). S. 485 - 498. HOBOKEN: WILEY. ISSN 1439-0507

Full text not available from this repository.

Abstract

The optimal approach to treat invasive fungal disease (IFD) caused by more than one fungal species is unknown. We documented the efficacy and safety of isavuconazole for treatment of IFDs caused by more than one fungal species. VITAL was a single-arm, international, open-label study evaluating the efficacy and safety of isavuconazole (200mg orally or intravenously every 8hours for 48hours, then once daily) for treatment of rare IFDs. The primary outcome was the overall response at Day 42; key secondary outcomes were overall responses at Day 84 and end of treatment (EOT), mortality at Days 42 and 84, and safety. This analysis includes patients with IFD caused by multiple fungal species. Fifteen patients were included in this analysis (including Aspergillus spp., n=11; without Aspergillus spp., n=4); median treatment duration was 97 days [range, 6-544] days). Overall treatment success was observed in 2/15 patients (13.3%) at Days 42 and 84, and 2/14 (14.3%) at EOT. All-cause mortality was 2/15 (13.3%) at Day 42 and 4/15 (26.7%) at Day 84. All patients had 1 treatment-emergent adverse event (TEAE); 12 patients (80.0%) had serious TEAEs; TEAEs led to discontinuation of isavuconazole in two patients (13.3%). Isavuconazole may be useful to treat some IFDs caused by multiple fungal species.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Marty, Francisco M. UNSPECIFIED orcid.org/0000-0002-3708-8734 UNSPECIFIED Cornely, Oliver A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mullane, Kathleen M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ostrosky-Zeichner, Luis UNSPECIFIED UNSPECIFIED UNSPECIFIED Maher, Rochelle M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Croos-Dabrera, Rodney UNSPECIFIED UNSPECIFIED UNSPECIFIED Lu, Qiaoyang UNSPECIFIED UNSPECIFIED UNSPECIFIED Lademacher, Christopher UNSPECIFIED UNSPECIFIED UNSPECIFIED Oren, Ilana UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmitt-Hoffmann, Anne-Hortense UNSPECIFIED UNSPECIFIED UNSPECIFIED Giladi, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Rahav, Galia UNSPECIFIED UNSPECIFIED UNSPECIFIED Perfect, John R. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-181968
DOI:	10.1111/myc.12777
Journal or Publication Title:	Mycoses
Volume:	61
Number:	7
Page Range:	S. 485 - 498
Date:	2018
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1439-0507
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language IN-VITRO ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLUS-FUMIGATUS; AMPHOTERICIN-B; INFECTION; PATIENT; CANDIDA; VORICONAZOLE; TRANSPLANTATION; SCEDOSPORIUM Multiple languages Dermatology; Mycology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/18196